Smith & Nephew plc
Smith & Nephew plc (SNNUF) Stock Overview
Explore Smith & Nephew plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
13.4B
P/E Ratio
33.05
EPS (TTM)
$0.47
ROE
0.08%
SNNUF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Smith & Nephew plc (SNNUF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $13.34.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 33.05 and a market capitalization of 13.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Deepak S. Nath
17,349
Building 5, Watford
2009